Trial · NCT07301970
Population Pharmacokinetics of Remifentanil in Low-Weight Critically Ill Patients
NCT07301970, Recruiting, Fudan University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Population Pharmacokinetics of Remifentanil in Low-Weight Critically Ill Patients. Trials, record NCT07301970. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07301970
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Population Pharmacokinetics of Remifentanil in Low-Weight Critically Ill Patients
- NCT number
- NCT07301970
- Status
- Recruiting
- Enrollment
- 45 participants, estimated
- Lead sponsor
- Fudan University
- Conditions
- Critical Illness, Pain
- Interventions
- Remifentanil
- First posted
- 2025-12-24
- Last updated
- 2025-12-24
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Plasma Concentration of Remifentanil | From the start of remifentanil administration, through the maintenance infusion phase, up to 2 hours after the end of infusion. | Peripheral arterial blood samples (1mL each) drawn from an existing indwelling arterial blood pressure (ABP) catheter will be collected to determine the plasma concentration of remifentanil (unit: ng/mL). A sparse and opportunistic sampling strategy is employed to capture the full pharmacokinetic profile. Sampling points typically include: 1. Absorption/Distribution Phase: Approximately 2 samples within the first 2 hours of administration; 2. Maintenance Phase: Samples collected during steady-state infusion, and following dose adjustments to capture the new steady state (typically after re-equilibration); 3. Elimination Phase: Approximately 3 samples within 2 hours after the end of infusion. |
| Secondary | Mean Arterial Pressure (MAP) | From baseline throughout the duration of drug infusion (up to approximately 48 hours). | Evaluation of hemodynamic stability by measuring the absolute value of MAP. Reported in mmHg. |
| Secondary | Plasma Concentration of Propofol | From the start of its administration, through the maintenance infusion phase, up to 2 hours after the end of infusion. | Plasma propofol concentrations will be measured in the subset of patients who receive propofol as a rescue sedative or co-medication. This data will be used as a covariate in the PK/PD analysis to differentiate the hemodynamic effects of propofol from those of remifentanil. |
| Secondary | Heart Rate | From baseline throughout the duration of drug infusion (up to approximately 48 hours). | Evaluation of hemodynamic stability by measuring Heart Rate. Reported in beats per minute. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07301970
GET https://conductscience.org/api/trials/v1/NCT07301970/registered